Certolizumab pegol in active rheumatoid arthritis

Clinical Trials Report


  1. 1.
    Maini R, St Clair EW, Breedveld F, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932–1939.PubMedCrossRefGoogle Scholar
  2. 2.
    Keystone EC, Kavanaugh AF, Sharp JT, et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400–1411.PubMedCrossRefGoogle Scholar
  3. 3.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al.: Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007, 357:239–250.PubMedCrossRefGoogle Scholar
  4. 4.
    Smolen J, Landewé RB, Mease P, et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009, 68:797–804.PubMedCrossRefGoogle Scholar
  5. 5.
    Fleischmann R, Vencovsky J, van Vollenhoven R, et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009, 68:805–811.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Division of Rheumatology and Clinical Immunology, Division of Pediatric RheumatologyUniversity of Pittsburgh, Children’s HospitalPittsburghUSA
  2. 2.PittsburghUSA
  3. 3.Division of Rheumatology and Clinical ImmunologyUniversity of PittsburghPittsburghUSA
  4. 4.PittsburghUSA

Personalised recommendations